Mink Therapeutics Inc (INKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $47.95M
Last updated: Nov 17, 2026 at 11:05 AM ET
Mink Therapeutics Inc (INKT) Earnings: Report Dates and Results
Mink Therapeutics (INKT) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Mink Therapeutics reported EPS of -$0.50, above the -$0.66 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INKT has an expected report date of Mar 29, 2027.
INKT Earnings Call
The latest INKT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 22 quarters below that had an estimate, INKT beat 14, missed 7 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 675.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.50 | -$0.66 | -$0.67 - -$0.50 | +24.24% | Beat | N/A | 2 | 1 up, 0 down | Nov 11, 2026 | $200000 |
| Jun 30, 2026 | -$0.62 | -$0.60 | -$0.60 - -$0.60 | -3.33% | Miss | N/A | 1 | 1 up, 0 down | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.57 | -$0.77 | -$0.77 - -$0.77 | +25.97% | Beat | N/A | 1 | 1 up, 0 down | May 15, 2026 | N/A |
| Dec 31, 2025 | -$0.56 | -$0.68 | -$0.68 - -$0.68 | +17.65% | Beat | N/A | 1 | 0 up, 3 down | Mar 17, 2026 | N/A |
| Sep 30, 2025 | -$0.65 | -$0.85 | -$0.91 - -$0.80 | +23.53% | Beat | N/A | 2 | 0 up, 3 down | Nov 14, 2025 | N/A |
| Jun 30, 2025 | -$1.06 | -$0.55 | -$0.73 - -$0.36 | -92.73% | Miss | N/A | 3 | 1 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.70 | -$0.61 | -$0.63 - -$0.59 | -14.75% | Miss | N/A | 2 | 0 up, 2 down | May 15, 2025 | N/A |
| Dec 31, 2024 | -$0.62 | -$0.08 | N/A | -675.00% | Miss | N/A | 3 | 2 up, 0 down | Mar 18, 2025 | $3.77B |
| Sep 30, 2024 | -$0.50 | -$0.80 | -$0.90 - -$0.70 | +37.50% | Beat | N/A | 3 | 3 up, 0 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.70 | -$0.97 | -$1.10 - -$0.90 | +27.84% | Beat | N/A | 3 | 0 up, 1 down | Aug 13, 2024 | N/A |
| Mar 31, 2024 | -$1.10 | -$1.53 | -$1.70 - -$1.40 | +28.10% | Beat | N/A | 3 | 0 up, 0 down | May 14, 2024 | N/A |
| Dec 31, 2023 | -$0.16 | -$0.15 | -$0.16 - -$0.14 | -6.67% | Miss | N/A | 3 | 0 up, 0 down | Mar 21, 2024 | N/A |
| Sep 30, 2023 | -$1.50 | -$1.82 | -$2.10 - -$1.60 | +17.58% | Beat | N/A | 4 | 0 up, 0 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$1.80 | -$1.97 | -$2.10 - -$1.60 | +8.63% | Beat | N/A | 4 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$1.70 | -$2.37 | -$2.60 - -$2.10 | +28.27% | Beat | N/A | 4 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.23 | -$0.21 | -$0.21 - -$0.21 | -9.52% | Miss | N/A | 4 | 0 up, 0 down | Mar 21, 2023 | $2.70B |
| Sep 30, 2022 | -$1.90 | -$2.33 | -$2.50 - -$2.10 | +18.45% | Beat | N/A | 4 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$1.80 | -$2.40 | -$2.50 - -$2.30 | +25.00% | Beat | N/A | 3 | 0 up, 0 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$2.30 | -$2.30 | -$2.40 - -$1.80 | 0.00% | In line | N/A | 3 | 0 up, 0 down | May 10, 2022 | N/A |
| Dec 31, 2021 | -$0.18 | -$0.41 | -$0.58 - -$0.24 | +56.10% | Beat | N/A | 2 | 0 up, 0 down | Mar 18, 2022 | $221.92M |
| Sep 30, 2021 | -$5.90 | -$2.00 | N/A | -195.00% | Miss | N/A | 2 | 0 up, 2 down | Oct 15, 2021 | N/A |
| Jun 30, 2021 | -$0.21 | -$0.28 | N/A | +25.00% | Beat | N/A | N/A | N/A | Sep 1, 2021 | N/A |
| Mar 31, 2021 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | N/A |
| Dec 31, 2020 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2021 | N/A |
| Sep 30, 2020 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | N/A |
| Jun 30, 2020 | -$0.16 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | N/A |
| Mar 31, 2020 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$0.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.97, after -$2.92 the year before. It was -$0.18 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.97 | N/A |
| Dec 31, 2024 | -$2.92 | N/A |
| Dec 31, 2023 | -$5.16 | N/A |
| Dec 31, 2022 | -$6.23 | N/A |
| Dec 31, 2021 | -$6.50 | N/A |
| Dec 31, 2020 | -$0.70 | N/A |
| Dec 31, 2019 | -$0.18 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,318 | 7 | |
| 2026Q2 | Jun 30, 2026 | 4,198 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,105 | 6 | |
| 2025Q4 | Dec 31, 2025 | 4,246 | 6 | |
| 2025Q3 | Sep 30, 2025 | 5,444 | 7 | |
| 2025Q2 | Jun 30, 2025 | 3,389 | 7 | |
| 2025Q1 | Mar 31, 2025 | 3,018 | 7 | |
| 2024Q4 | Dec 31, 2024 | 3,914 | 7 |
2026Q3 Earnings Call
Opening remarks
Stefanie Perna-Nacar Investor Relations Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and access plans, timelines for data releases, our named patient program, our cash resources and our partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings, including the Form 10-Q we filed this week, available on our website, for a detailed description of all these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer; Dr. Terese Hammond, Head of Inflammatory and Pulmonary Diseases; and Melissa Orilall, Principal Financial Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter. Dr. Buell?
Jennifer Buell President and Chief Executive Officer Thank you, Stefanie. Good morning, and thank you for joining us. A year ago on this call, we said that by this time, we expected to have a randomized trial running in critical illness, multiple clinical programs enrolling and a path toward pivotal development. All three are now in motion. This quarter brought that closer. Patients are being treated, data are accumulating, and physician demand has produced patient access outside of clinical trials and marks our first revenue with agenT-797. Over the course of this year, we have had a substantial amount of visibility. At AACR, the American Association for Cancer Research, in April, investigators from Memorial Sloan Kettering reported a 77% disease control rate in patients treated with agenT-797 in combination with botensilimab and balstilimab in PD-1-refractory gastroesophageal cancer. Following that, at the American Cell and Gene Conference here in Boston in May, we showed that the same off-the-shelf cells derived from the same donor can drive an antitumor response in cancer and a restorative anti-inflammatory and pathogen-clearance response in patients with respiratory distress. These cells read the disease and respond to it. These data were exemplified in the same year at the American Thoracic Society, the Military Health Science and Research Symposium and the Society for Immunotherapy in Cancer, where we added lung, clinical and senolytic data that I will cover shortly. Our strategy is deliberately focused. We're using randomized evidence in severe hypoxemic respiratory failure to establish a rapid development pathway for agenT-797, and with the validation of this technology, the case for deployable immune restoration in critical illness. We extend this platform into fibrosis, cancer and engineered iNKT medicines where the biology is differentiated.
Frequently Asked Questions About INKT
When is Mink Therapeutics's next earnings date?
Mink Therapeutics's next earnings report is expected for Mar 29, 2027.
Did INKT beat earnings estimates last quarter?
Yes. Mink Therapeutics reported EPS of -$0.50 for the quarter ended Sep 30, 2026, above the -$0.66 estimate, a 24.24% surprise.
What EPS do analysts expect from INKT next quarter?
The consensus EPS estimate for Mink Therapeutics for the quarter ending Dec 31, 2026 is -$0.52 from 4 analysts, with estimates from -$0.62 to -$0.41.
How often does INKT beat earnings estimates?
Mink Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -86.80%.
INKT pages: Overview, Earnings, Forecast, Financials, Competitors